The Maine Hospital Association has joined the American Hospital Association and several health systems in suing the federal government over planned changes to a prescription drug discount program used by hospitals serving low-income and rural communities.
The lawsuit challenges a new rebate model for the federal 340B Drug Pricing Program, which requires pharmaceutical manufacturers participating in Medicaid to provide discounted outpatient medications to eligible hospitals and other health care organizations.
Under the traditional system, participating providers generally receive the discounted price when purchasing eligible medications. The federal government's new pilot would instead require participating hospitals to pay the full price upfront for certain drugs and later seek rebates from manufacturers.
Hospitals argue that the change could force safety-net providers to temporarily carry substantially higher medication costs while also creating additional administrative work. They contend that the resulting cash-flow pressures could affect money available for patient care and other services, particularly at financially strained rural and safety-net hospitals.
The plaintiffs are asking a federal court in Maine to block the new rebate model before it takes effect. Their complaint alleges that the U.S. Department of Health and Human Services and its Health Resources and Services Administration exceeded their authority and failed to adequately account for the impact on participating health care providers.
The federal government has argued that a rebate approach can improve oversight of the 340B program and help prevent duplicate discounts and other problems associated with determining whether individual drug purchases qualify for reduced pricing.
The lawsuit is part of a broader dispute over the rapidly growing 340B program. Hospitals say savings generated through discounted medications help finance services for vulnerable patients, while drug manufacturers have raised concerns about program oversight and whether discounts always benefit the patients the program was designed to serve.
For Maine, the dispute is particularly significant because rural hospitals and health systems operate across large areas with relatively small populations, making their financial stability an ongoing concern.
The lawsuit does not immediately eliminate the federal government's planned changes. The courts will now determine whether the new rebate system can proceed as scheduled while the broader legal challenge is considered.
Should safety-net hospitals continue receiving drug discounts upfront, or could a rebate system provide better oversight without harming patient care?